Nav: Home

In multiple myeloma, different types of blood biopsies match up well with bone marrow tests

April 27, 2018

Bone marrow biopsies are the gold standard for diagnosing and monitoring the progression of multiple myeloma, but these procedures are far too invasive to perform at every patient visit. Scientists from the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard, however, have shown that two ways to measure multiple myeloma DNA in blood samples provide highly detailed sets of genetic information that agree well not just with each other but with results from bone marrow tests.

"Until now, we haven't had a good way to measure how multiple myeloma cell populations evolve from precursor stages to diagnosed disease, and then respond to treatments, says Irene Ghobrial, MD, a Dana-Farber medical oncologist. "This is where blood biopsies can make a huge difference--extending our understanding of multiple myeloma, and really giving us a timeline of how the disease progresses and responds to therapy."

The collaborative research examined blood biopsies that gathered multiple myeloma tumor DNA from two sources. One is circulating free DNA (cfDNA), scraps of DNA released into the bloodstream by dying cells. The other is circulating tumor cells (CTCs)--myeloma cells themselves.

"Our discovery that cfDNA and CTC analyses agree with each other at the comprehensive level is an important finding, because this means that routine genetic profiling of patient tumors from blood would be feasible," says Ghobrial, co-senior author on a paper reporting the work in Nature Communications.

The blood biopsy analyses followed a two-step sequencing approach, says Viktor Adalsteinsson, PhD, group leader of the Blood Biopsy Team at the Broad Institute and co-senior author on the paper. The first step, developed by his team and called "ultra-low pass" whole genome sequencing, was a cost-effective method to identify blood samples with tumor DNA fraction of at least 5-10%, allowing more comprehensive genetic analysis. In the second step, the researchers performed whole exome sequencing (analyzing the protein-coding regions of the genome) on those samples.

The investigators examined cfDNA from 107 patients and CTCs from 56 patients. The scientists then matched up cfDNA with bone marrow data from nine patients, and compared all three forms of biopsy in four additional patients. Overall, the gene profiles overlapped closely--demonstrating about 99% agreement between liquid and bone marrow biopsies for tumor gene mutations, for instance.

Such high levels of agreement suggest that the two forms of liquid biopsy might be used interchangeably to track patients with multiple myeloma, the researchers say, and employing both techniques might further increase the chances of understanding the disease in each patient.

It's also possible that blood biopsies will offer more comprehensive genetic information than bone marrow tests, says Salomon Manier, MD, PhD, co-first author on the paper and a former graduate student in the Ghobrial lab.

Knowing the entire genetic spectrum of disease is crucial to individualize treatment, especially given the growing number of therapeutic options for multiple myeloma, Manier points out. But bone marrow biopsies collect cells from just one location, so those tests can miss nearby cells with quite different characteristics.

"We can't do personalized medicine with a single bone marrow biopsy," he says. "We need these blood biopsies to help guide treatment, because patients' tumors change over time."

The investigators emphasize that results of their study must be confirmed in larger patient cohorts, now ongoing, before blood biopsies can be brought into clinical use.

Among their next steps, the scientists aim to develop methods that provide more detailed and clinically appropriate genetic information, and to hone techniques that work in blood samples with lower fractions of cancer DNA. "Our ultimate goal is to eventually use all the samples to monitor disease progression," says Jihye Park, PhD, researcher in the Ghobrial lab and co-first author on the paper.

"The technology is basically there, says Ghobrial. "Our patients are so excited to see these tests, and now we need to develop clinical tools that become part of routine testing."

"These noninvasive techniques can really open the door for longitudinal study of cancer evolution and progression," says Adalsteinsson, whose group pursues many projects to comprehensively sequence solid tumors as well as blood cancers. "We believe it's important to look broadly at a patient's cancer genome and how it changes over time--to identify not only the known actionable mutations of today but also to discover new ones that will inform better and more effective treatments of tomorrow."
-end-
Other Dana-Farber co-authors include Marzia Capelletti, Mark Bustoros, C.J. Liu, K.Z. Salem, Daisy Huynh, Claudia Freymond, A. Yosef, Adriana Perilla-Glen and Eliezer Van Allen. Broad contributors include Samuel Freeman, Gavin Ha, Justin Rhoades, Sarah Reed, Gregory Gydush, Denisse Rotem, J. Christopher Love and Gad Getz. Laurent Garderet of St-Antoine University Hospital and Shaji Kumar of the Mayo Clinic also were-coauthors. Lead funders for the work were the National Cancer Institute, the Multiple Myeloma Research Foundation, the Leukemia & Lymphoma Society, and the Gerstner Family Foundation.

Dana-Farber Cancer Institute

Related Multiple Myeloma Articles:

Study finds racial disparities in treatment of multiple myeloma patients
Among patients with multiple myeloma, African-Americans and Hispanics start treatment with a novel therapy significantly later than white patients, according to a new study published today in Blood Advances.
NEJM publishes bb2121 Phase 1 data in patients with multiple myeloma
Celgene Corporation and bluebird bio announce results from ongoing multicenter Phase 1 study of bb2121 anti-BCMA CAR T cell therapy in patients with multiple myeloma published in the New England Journal of Medicine.
Multiple myeloma: DNA rearrangement may predict poor outcomes
In multiple myeloma, Ig lambda translocations may indicate poor outcomes and resistance to immunomodulatory drugs such as lenalidomide.
Computational platform optimizes multiple myeloma treatments
Masturah Bte Mohd Abdul Rashid and colleagues have developed a new platform that optimizes drug combinations for the treatment of multiple myeloma (MM), an incurable blood cancer.
Screening high-risk individuals can reduce multiple myeloma mortality
Multiple myeloma is a rare incurable disease that is diagnosed in more than 30,000 people each year in the United States.
Carfilzomib can lead to cardiovascular toxicity in multiple myeloma patients
The proteasome inhibitor carfilzomib has taken on an increasing role in the treatment of multiple myeloma, but new research from the Abramson Cancer Center of the University of Pennsylvania shows the therapy comes with the risk of cardiovascular problems in a higher than expected percentage of patients.
Sequencing offers clues to progression toward multiple myeloma
Researchers at Dana-Farber Cancer Institute have carried out the largest genomic analysis of patients with smoldering multiple myeloma (SMM), a precursor to full-blown blood cancer that doesn't show outward symptoms.
Tracking how multiple myeloma evolves by sequencing DNA in the blood
Although people with multiple myeloma usually respond well to treatment, the blood cancer generally keeps coming back.
CAR T, immunotherapy bring new hope for multiple myeloma patients
Two investigational immunotherapy approaches, including chimeric antigen receptor (CAR) T cell therapy, have shown encouraging results in the treatment of multiple myeloma patients who had relapsed and were resistant to other therapies.
In multiple myeloma, high levels of enzyme ADAR1 are associated with reduced survival
Using a database of multiple myeloma patient samples and information, researchers at University of California San Diego School of Medicine found that high ADAR1 levels correlate with reduced survival rates.
More Multiple Myeloma News and Multiple Myeloma Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

Risk
Why do we revere risk-takers, even when their actions terrify us? Why are some better at taking risks than others? This hour, TED speakers explore the alluring, dangerous, and calculated sides of risk. Guests include professional rock climber Alex Honnold, economist Mariana Mazzucato, psychology researcher Kashfia Rahman, structural engineer and bridge designer Ian Firth, and risk intelligence expert Dylan Evans.
Now Playing: Science for the People

#540 Specialize? Or Generalize?
Ever been called a "jack of all trades, master of none"? The world loves to elevate specialists, people who drill deep into a single topic. Those people are great. But there's a place for generalists too, argues David Epstein. Jacks of all trades are often more successful than specialists. And he's got science to back it up. We talk with Epstein about his latest book, "Range: Why Generalists Triumph in a Specialized World".
Now Playing: Radiolab

Dolly Parton's America: Neon Moss
Today on Radiolab, we're bringing you the fourth episode of Jad's special series, Dolly Parton's America. In this episode, Jad goes back up the mountain to visit Dolly's actual Tennessee mountain home, where she tells stories about her first trips out of the holler. Back on the mountaintop, standing under the rain by the Little Pigeon River, the trip triggers memories of Jad's first visit to his father's childhood home, and opens the gateway to dizzying stories of music and migration. Support Radiolab today at Radiolab.org/donate.